ARA-290

ARA-290 is an 11-amino acid helix B surface peptide (HBSP) derived from the non-erythropoietic portion of erythropoietin (EPO). It is designed to selectively activate the Innate Repair Receptor (IRR) — a tissue-protective heteroreceptor complex consisting of the EPO receptor subunit (EPOR) and the common beta chain (CD131/βc) — without activating the homodimeric EPOR (EPOR2) complex responsible for erythropoiesis.

This receptor selectivity allows ARA-290 to deliver the cytoprotective, anti-inflammatory, and neuroregenerative benefits of EPO without the hematopoietic side effects (thrombosis risk, polycythemia) that limit therapeutic EPO use. ARA-290 has undergone clinical trials for painful small fiber neuropathy (SFN) in sarcoidosis patients, where it improved corneal nerve fiber density and pain scores, providing human clinical validation for its neuroprotective mechanism.

• Innate Repair Receptor (EPOR/CD131 heterodimer) pharmacology
• Neuroprotection and peripheral nerve fiber regeneration studies
• Non-hematopoietic EPO signaling and cytoprotection research
• Small fiber neuropathy and chronic pain preclinical models
• Anti-inflammatory mechanisms in peripheral tissue injury models
• Receptor selectivity: IRR vs homodimeric EPOR (EPOR2) studies

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

Innate repair receptor peptide studied for neuropathic pathways.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.